# Bevacizumab, Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

> **NCT00387699** · PHASE2 · COMPLETED · sponsor: **Eastern Cooperative Oncology Group** · enrollment: 79 (estimated)

## Conditions studied

- Lung Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** cisplatin
- **DRUG:** etoposide
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00387699
- **Lead sponsor:** Eastern Cooperative Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2007-10
- **Final completion:** 2014-04
- **Target enrollment:** 79 (ESTIMATED)
- **Last updated:** 2015-04-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00387699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00387699, "Bevacizumab, Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT00387699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*